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Abstract: 
Background: Potassium bromate (KBrO3), a food additive, has been used in many bakery products as an 
oxidizing agent. It has been shown to induce renal cancer in many in-vitro and in-vivo experimental models 
Objectives: This study evaluated the carcinogenic potential of potassium bromate (KBrO3) and the 
chemopreventive mechanisms of the anti-oxidant and anti-inflammatory phytochemical, curcumin against 
KBrO3-induced carcinogenicity 
Method: Lactate dehydrogenase (LDH) cytotoxicity assay and morphological characteristics were used to 
assess curcumin's cytoprotective potential against KBrO3 toxicity. To assess the chemopreventive potential of 
curcumin against KBrO3-induced oxidative insult, intracellular H2O2 and the nuclear concentration of the DNA 
adduct 8-OHdG were measured. PCR array, qRT-PCR, and western blot analysis were used to identify 
dysregulated genes by KBrO3 exposure. Furthermore, immunofluorescence was used to evaluate the ciliary 
loss and the disturbance of cellular tight junction induced by KBrO3. 
Results: Oxidative stress assays showed that KBrO3 increased the levels of intracellular H2O2 and the DNA 
adduct 8-OHdG. Combination of curcumin with KBrO3 efficiently reduced the level of H2O2 and 8-OHdG while 
up-regulating the expression of catalase. PCR array, qRT-PCR, and western blot analysis revealed that KBrO3 
dysregulated multiple genes involved in inflammation, proliferation, and apoptosis, namely CTGF, IL-1, and 
TRAF3. Moreover, qRT-PCR and immunofluorescence studies showed that KBrO3 negatively affected the tight 
junctional protein (ZO-1) and induced a degeneration of primary ciliary proteins. The negative impact of KBrO3 
on cilia was markedly repressed by curcumin. 
Conclusion: Curcumin could potentially be used as a protective agent against carcinogenicity of KBrO3  
Keywords: 
Potassium bromate (KBrO3); chemoprevention; curcumin; primary cilia; kidney cancer; inflammation 
1. INTRODUCTION 
              Potassium bromate (KBrO3), a food additive, has been used in different bakery products as an oxidizing 
agent. In 2005, the use of KBrO3 as a food additive was banned by countries of the European Union, Canada, 
Japan, China, India, and South America. Surprisingly, it has not been banned by the FDA in the US and still 
can be found in some bakery products [1, 2]. KBrO3 was shown to induce renal cancer in many in-vitro and in-
vivo experimental models [3-5]. Shiao et al found that rats exposed to KBrO3 in drinking water caused a 
mutation in the Von Hippel-Lindau tumor (VHL) gene, a crucial tumor suppressor that has been found to be 
 
 mutated in renal cell carcinomas [6]. KBrO3, was found to induce oxidative DNA damage and DNA adduct 
formation that lead to various gene mutations. For instance, the formation of the mutagenic 8-hydroxy 
deoxyguanosine (8-OHdG) was detected following the exposure of porcine kidney cells to KBrO3 [7]. 
Interestingly, KBrO3 was found to interact with GSH to form the highly reactive 8-oxodeoxyguanosine (8-
oxodG), thus causing DNA double strand break  [8, 9] . 
Following DNA damage, many genes including those controlling apoptosis and inflammation are 
dysregulated. For instance, Bader and Hsu mentioned that many pro-inflammatory genes such as HIF1a, HIF2a, 
TNF-α, TGF-β, and NF-KB were found to be up-regulated in response to DNA damage that eventually induced 
VHL mutation [10] . 
Primary cilia are immotile sensory organelles that play an important role in cell differentiation, polarity, 
and quiescence. They can receive mechanical and chemical signals from other cells as well as, from the 
surrounding environment [11]. Normally, cells assemble cilia on their membranes when they "stop" dividing, 
exit the cell cycle, and start to differentiate [12]. However, cells tend to lose cilia when they re-enter the cell 
cycle and mitosis [13]. In most renal cell carcinomas where the suppressor VHL gene is inactivated, Schraml 
et al found that ciliary loss in clear cell renal cell carcinoma (ccRCC) was strongly associated with the mutation 
of this tumor suppression gene. In contrast, the author found that in papillary renal cell carcinomas, the 
frequency of cilia was higher than ccRCC and the ciliary loss was VHL independent, which points to the 
differences in the biological pattern between these types of cancer cells [14]. 
Chemoprevention is a novel aspect in cancer development and treatment referring to the use of natural, 
semi-synthetic or synthetic compounds to halt, stop, or reverse tumor formation and progression [15]. 
Chemopreventives can block tumor initiation; therefore, they are termed blocking agents. For instance, anti-
oxidants, free radical scavengers, phase I drug-metabolizing enzymes inhibitors, and phase II drug-metabolizing 
enzymes inducers are deemed cancer blocking agents. Whereas compounds that halt the stages of tumor 
promotion and progression are referred to as tumor suppressors. Induction of apoptosis, terminal cell 
differentiation, inhibition of cell proliferation and clonal expansion, and alteration of gene expression of 
preneoplastic tumors are examples of tumor suppression [15-17] . 
Curcumin, also known as diferuloylmethane, is a polyphenolic compound derived from the root and 
rhizome of the plant Curcuma longa [18, 19]. Curcumin has a chemoprevention potential owing to its anti-
oxidant, anti-inflammatory, immunomodulatory, and pro-apoptotic potential[20]. While curcumin abrogates 
several oncogenic pathways such as NF-KB, Akt/PI3K and MAPK, it has recently been found to induce anti-
tumor potential via epigenetic modulations of critical genes. For instance, it dysregulates several oncogenic and 
tumor suppressor miRNA, namely, miR-21, miR-17-5p, miR-22, miR-15a, miR-20a, and miR-27a [21, 
22]  
 
       This study aimed at investigating the carcinogenic potential of KBrO3 and the mechanisms by which 
curcumin can prevent the carcinogenic insults of KBrO3 on the renal epithelial cells (RPTEC/TERT1).  
Moreover, our group has reported that targeting RPTEC/TERT1 with a subtoxic concentration of KBrO3 was 
associated with loss of primary cilia [23], therefore this study also investigated the preventive potential of 
curcumin against KBrO3 induced deciliation, and thus inhibited proliferation and dedifferentiation. 
2. MATERIALS AND METHOD 
 2.1. Cell culture and treatment 
The human renal proximal tubular epithelial (RPTEC/TERT1) [24] and ACHN cell lines were obtained 
from the American Tissue Culture Collection (ATCC). Cells were maintained in low glucose (5 mM) 
Dulbecco’s Modified Eagle / Nutrient Mix F-12 medium supplemented with 5g/ml insulin, 5g/ml transferrin, 
5g/ml selenite (ITS), 36ng/ml hydrocortisone, 10ng/ml epidermal growth factor (EGF) (Sigma‐Aldrich) 50 
U/ml penicillin, 50g/ml streptomycin (P/S), and 2mM L-glutamine (Gibco, Life Technologies). ACHN cells 
were maintained in Minimum Eagle Medium (Sigma‐Aldrich) with 10% FBS and P/S. Both cell lines were 
incubated at 37o C in a 5% CO2 humidified atmosphere. 
RPTEC/TERT1 were seeded at a density of 1x106 cells/ml. Cells were maintained for 10 days after 
reaching 100% confluency to allow stabilization of the monolayer [23]. While ACHN cells were seeded at the 
same density one day in advance before the treatment. KBrO3 and curcumin were purchased from (Sigma-
Aldrich, Taufkirchen, Germany). KBrO3 was dissolved in water to prepare 100mM stock solution which was 
then further diluted with culture medium to get the indicated concentrations. Curcumin and silymarin were 
dissolved in DMSO to prepare stock solutions of 250 mM and 50mM, respectively. They were then further 
diluted with culture medium to final concentration 200 µM and 25 µM, respectively. In most experiments, 
where curcumin or silymarin was used, control cells were exposed to a maximum 0.1% DMSO. 
2.2. Lactate dehydrogenase(LDH) release assay (LDH) 
The LDH assay was performed using a Roche kit (Roche Diagnostics, Mannheim, Germany). Briefly, 
RPTEC/TERT1 cells were cultured at density of 1x106 cells/ ml in 24-well plates and allowed to form a fully 
confluent monolayer. 10 days post confluency, cells were treated with six different concentrations of KBrO3 
(0.5,1,2,3,5, and 10 mM) only or in a combination with 25µM curcumin for 24h. The positive control for 
maximum LDH release or 100% cell death was prepared by treating cells with 2% Triton-X 100 for 5 min at 
37°C. Following 15min incubation of cell supernatants with the reaction mixture (provided by the kit), the 
absorbance was measured at 490nm using Spectamax2 plate reader (Molecular devices, Winnersh/ UK). LDH 
release was expressed as a percentage of the maximum LDH activity.  
2.3. Phase contrast microscopy 
RPTEC/TERT1 cells at 1x106 cells/ ml were cultured in 24- well plates and allowed to form a fully 
confluent monolayer. 10 days post-confluency, cells were treated with KBrO3 (10mM) only or in a combination 
with 25µM curcumin for 24h at 37°C. Cellular morphology was observed by phase contrast microscopy using 
a JVC high-resolution digital camera (KY-F55BE) attached to a Nikon TMS phase contrast microscope. 
Micrographs were processed using ImageJ v.1.49.  
2.4. Determination of intracellular H2O2 concentration 
Intracellular hydrogen peroxide (H2O2) concentrations were measured using Amplex red assay kit 
(Thermo Fisher scientific, Carlsbad, CA) following the manufacturer instructions. Briefly, cells were cultured 
in 12 well culture plates. Following treatment, cells were lysed in 200 µl ice-cold lysis buffer (0.1% Triton X-
100 in 0.05 M sodium phosphate buffer, pH 7.4). Following this, lysates were transferred to pre-chilled 
microfuge tubes and vortexed every 3 min for 15 min for complete cell homogenization. Tubes were centrifuged 
at 14,000 g at 4C for 15 min. A volume of 50 µl of supernatants and standard H2O2 solutions (0, 0.05, 0.1, 
 0.25, 0.5, 0.75, 1, 1.25, 2, and 5 µM) were loaded in 96-well opaque black microplate. An equal volume of 
Amplex Red reaction mixture (0.1 mM Amplex red reagent and 0.2 U/ml horseradish peroxidase in 1X reaction 
buffer) was added to the pre-loaded wells to initiate the reaction. The fluorescence was measured kinetically 
every 30 sec for 30 min at excitation and emission wavelengths of 530 and 590 nm, respectively using a 
scanning microplate reader (Molecular Devices Inc, Sunnyvale, CA, USA). Intracellular H2O2 concentration 
was calculated using the standard curve and normalized to the total protein content. 
2.5. Determination of intra-nuclear concentration of 8-OHdG 
This assay consists of 4 stages: DNA extraction, determination of DNA concentration, DNA digestion, 
and measuring the concentration of the DNA adduct 8-OHdG. 
DNA was extracted from cells using WAKO DNA Extractor WB Kit (Wako, Osaka, Japan) which 
contains sodium iodide (NaI) as chaotropic agent to minimize the oxidation of DNA during the extraction. The 
concentrations of DNA solutions were calculated using the Thermo Fisher Scientific NanoDrop 2000 (Thermo 
Fisher Scientific, Wilmington, DE, USA). The Wako 8-OHdG Assay Preparation Reagent kit was used 
exclusively to digest DNA and release 8-OHdG. Determination of the intranuclear 8-OHdG concentration was 
performed using an enzyme-linked immunosorbent assay (ELISA) kit (Highly Sensitive 8-OHdG Check ELISA 
kit, Japan Institute for the Control of Aging, Fukuroi, Japan). Briefly, a volume of 50 µl of digested DNA 
samples and standard concentrations were loaded to the provided ELISA plate. A volume of 50 µl primary 
antibody per a well was added and incubated overnight at 4°C. Next day, the well contents were poured off and 
washed three times using 250μl/well washing solution. The wells were incubated with100 μl/ well of secondary 
antibody for 1h at room temperature. The plate was washed before adding a chromatic solution and incubated 
for 15 min at room temperature in a dark place. Finally, the reaction was terminated by adding 100μl of the 
reaction terminating solution. The absorbance was read at 450 nm.  
2.6. Immunofluorescent labeling 
For immunofluorescent labeling experiments, cells were cultured in 8-well chamber slides (Millipore, 
USAand allowed to form a fully confluent monolayer. 10 days post-confluency, cells were treated with DMSO-
containing medium, 5.5mM KBrO3, 25µM curcumin, or a combination of both for 24h at 37 °C. Following 
treatment, cells were washed with PBS three times and fixed with 3.7% formaldehyde for 20 min at room 
temperature. Cells were then washed three times with PBS and permeabilized with 0.2%(v/v) Triton-X 100 in 
PBS. Background was reduced by blocking nonspecific signals with 0.5% (w/v) BSA in PBS. The ciliary 
markers Acetylated α-tubulin and Arl  13B were labeled using a mouse anti-human antibody (1:400) (Sigma-
Aldrich, Taufkirchen, Germany) and a rabbit anti-human antibody, respectively. ZO-1 was labeled using a 
rabbit anti-human antibody (1:300) (Zymed, Invitrogen, South San Francisco, CA). Nuclei were stained with 
Hoechst 33342 (1:1000) (Sigma-Aldrich, Taufkirchen, Germany). Slides were imaged using a Zeiss A-Plan 
40X/0.65 objective and a Zeiss M1 Upright AxioImager with CoolLED P3000 light source or a Zeiss C-Plan-
Apochromat 40X/1.3 objective and a Zeiss LSM510 UVMETA confocal microscope. Images were 
deconvolved using Auto Quant-X3 deconvolution software (Version 3.0.3) (Media Cybernetics Inc.) at 5 
iterations. Images were adjusted for brightness and contrast using Fiji/ImageJ (Fiji.sc/).  
2.7. RNA extraction and preparation of cDNA 
 RPTEC/TERT1 cells were seeded and treated as described earlier using 6-well plate format. TRIzol 
method was used to extract total RNA. The same method was applied to extract the total RNA from the ACHN 
cells after 24h of growth. Briefly, TRIzol (Life Technologies, USA) was used to lyse cells (1ml per a well). 
Cells were then homogenized by passing through pipette tip several times. Following the homogenization, 
200µl of 1–bromo–3–chloropropane (BCP), a chloroform derivative, was added to the homogenate, mixed by 
vertexing, incubated for 3 min at room temperature, then centrifuged at 12,000 × g at 4°C for 15min. The 
mixture was separated into three phases: aqueous (RNA), interphase and a red lower organic layer (DNA and 
protein). The aqueous phase was transferred into a clean microfuge tubes then 500µl isopropanol was added to 
precipitate RNA. Following centrifugation at 12,000 × g at 4°C for 15 min, the supernatant was discarded and 
the pellets were washed with 500µl of 75% ethanol to remove further impurities. The microfuge tubes were 
finally centrifuged at 7500g at 4°C for 5 min. The supernatant was discarded and RNA pellets were dissolved 
in ddH2O. For further RNA purification and removing of genomic DNA contamination, mRNeasy and DNase 
Max kit (Qiagen, UK) were used according to the manufacturer protocol. The yield of the RNA was assessed 
by measuring the optical density at 260 nm and 280nm using a Nanodrop ND-1000 spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE, USA). The purity of RNA samples was assessed based on the absorbance 
ratio of 260:280 which should be ≥1.8. A total RNA of 1µg was reversed transcribed to cDNA using a RevertAid 
H Minus First Strand cDNA synthesis Kit (Fermentas GmbH, St. Leon-Rot, Germany) according to the 
manufacturer’s instructions. 
2.8. Quantitative Real-Time PCR Analysis 
Quantitative expression of a total of 192 genes (list of genes provided in the supplementary Table1) 
involved in inflammation, angiogenesis, and apoptosis were evaluated using real-time PCR ABI PRISM® 
7900HT (Foster City, California USA). These were customized PCR arrays designed by (Sigma-Aldrich, 
Taufkirchen, Germany) Corp. For the PCR array experiment, 20μL cDNA of each individual treatment was 
diluted up to 170μL using distilled water. Three biological replicates of a single treatment group were pooled 
and analyzed. The real-time PCR mix (20μL/well) contained 1μL of pooled cDNA, 3μL water, 6μL primer mix, 
and 10μL SYBR green master mix. The thermal cycle conditions were 95°C for 15min followed by 45 cycles 
of 94°C for 15 sec, 55 °C for 30 sec, and 70 °C for 30 sec. The dissociation stage was set at  95 °C for 15 sec, 
60°C for 15 sec, and 95°C for 15 sec, as previously described [25] The mRNA abundances were expressed in 
"cycle threshold" (Ct) values, which represents the number of PCR cycles after which the PCR product crosses 
a threshold value. A Ct value of 35 was used as the cut-off limit. The normalization of gene expression was 
carried out based on the abundance of the house-keeping genes βactin (ACTB), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and beta-glucuronidase (GUSB).  
Validation of the PCR array was performed using single tube TaqMan-probe based gene expression assays 
(Applied Biosystems, Foster City, CA, USA).  Normalization of genes expression was carried out using the 
house-keeping gene β-actin. The PCR reaction mixture (10μL) consisted of 0.5μL cDNA, 3.5μL nuclease free 
water, 0.5μL primer mix, 0.5μL loading control (β-actin), and 5μL TaqMan master mix. The thermal cycle 
conditions were as follows: 50°C for 2 min, 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s, 60 °C 
for 1 min. Samples were loaded in an optical 384 well plate in duplicates (10μL/ well) and Ct values <35 were 
used as the cut-off limit. For the analysis of both PCR array and qRT-PCR, the 2−ΔΔCt method was applied. 
Briefly, average ΔCt was calculated as the difference of Ct values of any target gene from the average of the Ct 
 value of the reference gene (s). Then, fold change was calculated as 2(−average ΔCt target gene)/2(−average ΔCt reference gene). 
A fold difference cut-off point was set at ≥2.0 
2.9. Western blot analysis 
Western blot analysis was carried out according to the standard method by Buchmann [26]. Following cell 
treatment, the media was removed, and the cells were lysed by using RIPA buffer (Sigma-Aldrich, Taufkirchen, 
Germany). Total protein concentration was determined by Bradford method using BCA protein assay kit 
(Pierce, Rockford, IL, USA) according to the manufacturer protocol. Equal amounts of 20µg of whole cell 
lysates were placed in each lane and subject to SDS-PAGE electrophoresis, then transferred to a 0.2µm pore 
size Whatman Protran® nitrocellulose membrane (Thermo Fisher Scientific, Wilmington, DE, USA) using a 
semi-dry transfer system. After the transfer, the membranes were blocked by incubation with TBS-T buffer (50 
mM tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween 20) containing 5% non-fat milk or BSA for 1hr at room 
temperature. The membranes were then incubated overnight at 4°C with CTGF primary antibody (1:1000) 
(Santa Cruz, USA) and GAPDH (1:10,000) (Cell Signaling Technology Inc, Danvers, MA, USA). Next day, 
the blots were washed with T-BST then incubated with TBS-T/ 5% non-fat milk containing an appropriate 
secondary antibodies coupled with horse radish peroxidase (HRP) (Cell Signaling Technology Inc, Danvers, 
MA, USA) for 1h at room temperature. Immunodetection was performed using the SuperSignal West Pico 
Substrate (Thermo Scientific, Rockford, IL, USA).  
2.10. Statistical Analysis 
All experiments were repeated at least three times. Statistical analyses were performed using Graph Pad 
Prism 5.0. Data was analyzed using one-way analysis of variance (ANOVA). Comparisons between different 
treatment groups were made by Newman-Keuls Multiple Comparison post-test. Results were expressed as the 
mean +/- standard error of the mean (SEM). A probability of 0.05 of less was deemed statistically significant. 
 
3. Results 
3.1. Curcumin protected RPTEC/TERT1 against KBrO3 - induced cytotoxicity  
The potential cytoprotective effect of curcumin was investigated by comparing the activity of the released 
LDH following the exposure to KBrO3 alone and KBrO3/ curcumin combination. The morphological pattern of 
cells was assessed using phase contrast microscopy. As shown in Fig.1a, KBrO3 sharply increased the relative 
activity of LDH at 10mM KBrO3 concentration. The combination of KBrO3 with curcumin exhibited an 
extremely significant (p< 0.001) lowering of LDH release compared to KBrO3 treatment only. These findings 
revealed that curcumin exhibited a cytoprotective potential against KBrO3 induced cell death 
The effect of each treatment on cellular morphology was assessed using phase contrast microscopy 
(Fig.1b). When RPTEC/TERT1 cells were treated with DMSO (i) or with curcumin (ii), the cells showed 
normal cobblestone appearance, tight interconnections, and formed characteristic domes. Such morphological 
characteristics reflect an intact cellular transport system and indicated that the cells were “happy”, “healthy”, 
and fully differentiated. Under toxic conditions (iii), KBrO3 caused severe cellular damage with a complete loss 
of domes and loss of tight junctions between cells. Curcumin clearly minimized KBrO3-induced cellular damage 
 and loss of tight junctions. However, it only partially re-established the characteristic domes of RPTEC/TERT1 
cells (Fig.1.b).  
Following 24h exposure, the toxic (IC50) and the subtoxic (IC10) concentrations of KBrO3 were estimated 
to be 5.5 and 7.5mM, respectively using an LDH release assay (Fig.1c).  
 
 
Figure 1. Examination of the cytoprotective effects of curcumin measured by cytotoxicity assay and 
assessed by morphological characteristics. 
Fig.1a: The cytoprotective potential of curcumin was assessed using the LDH cytotoxicity assay. 
RPTEC/TERT1 cells were treated either with the indicated concentrations of KBrO3 only or a combination of 
KBrO3 concentrations with 25µM curcumin. The figure represents mean± SEM of six independent 
experiments. (*** = p<0.001) 
Fig.1b: Analysis of the morphological characteristics of RPTEC/TERT1 cells. Cells were seeded in 24 well 
plates, 10 days post 100% confluency, the cells formed fluid filled dooms which reflect a well-functioning 
transport system. (i) RPTEC/TERT1 were treated with 0.1% DMSO (control), or (ii) with 25µM curcumin for 
24h. The domes were maintained and cells were morphologically unaffected by the treatment. (iii) Cells were 
treated with 10mM KBrO3;. (iv) Cells were treated with the combination of 10mM KBrO3+ 25µM curcumin 
for 24 hr.  
  Fig.1c: Estimation of subtoxic IC10 and the toxic IC50 concentrations of KBrO3. RPTEC/TERT1 cells 
were seeded in 24 well plates. 10 days post 100% confluency, they were treated with the indicated 
concentrations of KBrO3 to estimate subtoxic IC10 and the toxic IC50 concentrations. 2% Triton-TX100 was 
used as a positive control of cell death. The figure represents mean± SEM of six independent experiments. 
 
3.2. Curcumin suppressed KBrO3 induced oxidative stress and DNA damage 
The potential chemopreventive activity of curcumin was further assessed by comparing the level of 
oxidative stress following the exposure of RPTEC/TERT1 cells to KBrO3 alone or in combination with 
curcumin. In this context, intracellular H2O2 and 8-OHdG concentrations were measured. Of note, at both IC10 
and IC50 concentrations, KBrO3 significantly increased the level of H2O2 (p<0.05) (Fig.2a,b), and 8-OHdG (p< 
0.001)  (Fig.2c,d) compared to the control or curcumin-only treatment. The combination of curcumin with IC10 
or IC50 KBrO3 concentrations significantly (p<0.05) inhibited the levels of both H2O2 and 8-OHdG compared 
to KBrO3 treatment only (Fig.2a, b, c and d). In addition, KBrO3 significantly (p<0.05) reduced catalase gene 
expression compared to the control or curcumin only treatment. The combination of curcumin with KBrO3, 
significantly (p<0.05) reversed the  negative effect of KBrO3 by upregulating catalase gene expression (Fig.2e).  
 
  
Figure 2. Analysis of Curcumin protection on RPTEC/TERT1 against KBrO3 induced oxidative 
stress and DNA adduct formation 
Fig.2a, b) Cells were seeded in 24 well plates until fully confluent. After 10 days, cells were treated with 
0.1% DMSO (control), curcumin, KBrO3 and a combination of KBrO3 + curcumin. Intracellular concentration 
of H2O2 was detected using the Amplex Red Hydrogen Peroxide Assay Kit. The data represents three 
independent experiments, *= p< 0.05. . 
Fig.2c,d) DNA adduct formation was investigated by measuring the intracellular concentration of the 
DNA adduct 8-OHdG, using the Highly Sensitive 8-OHdG Check ELISA kit following the manufacturer kit 
instructions. The data represents three independent experiments. *= p< 0.05, **= p<0.01, and ***=p <0.001. 
 
Fig.2e) Catalase gene expression was examined in KBrO3 (5.5mM) treated RPTEC/TERT1 cells after 
24h treatment by RT-PCR  analysis. (* = P < 0.05). 
 
3.3. KBrO3 induced dysregulation of target genes 
 The effects of KBrO3 on a panel of 192 genes, was assessed using SYBR green based PCR array 
technology. These genes are involved in the regulation of inflammation, oxidative stress, angiogenesis, 
epithelial-mesenchymal transition (EMT), ciliary formation, and apoptosis (supplementary table 1).  
Following the exposure of RPTEC/TERT1 cells to 5.5mM KBrO3, many genes were dysregulated, as  shown in 
table 1. Namely, connective tissue growth factor (CTGF) was the first most overexpressed gene, while 
interleukin (IL)1-receptor 1 (IL-1R1) was the first most downregulated compared to the untreated 
RPTEC/TERT1 cells. Genes that were differentially dysregulated in renal cancerous ACHN cells compared to 
normal RPTEC/TERT1 cells are shown in table 2. In this regard, CTGF was one of the top three most 
overexpressed genes, while IL-1R1 was the most down-regulated gene. The status of genes, that were up-/down-
regulated following the exposure of RPTEC/TERT1 cells to KBrO3, was compared to the congruent genes in 
ACHN cells. ACHN cell line was used as a positive control of carcinogenesis.  
Interestingly, we found that a total of 47 genes were differentially dysregulated in the same manner in both 
KBrO3 treated RPTEC/TERT1 and in the cancerous ACHN cell lines (Table 3).  
 
Table 1: List of genes dysregulated following the exposure of RPTEC/TERT1 to KBrO3 for 24h 
compared with untreated RPTEC/TERT1 cells 
Genes with markedly decreased expression Genes with markedly increased expression 
Fold 
decrease Gene name Gene 
Fold 
increase Gene name Gene 
-57.7 Interleukin (IL)1-receptor 1  IL1R1 197.55 Connective tissue growth factor CTGF 
-30.89 Toll-like receptor 3 TLR3 37.53 Plasminogen activator inhibitor-1 PAI1 
-26.57 Chemokine (C-X-C Motif) Ligand 1 CXCL1 29.92 Resistin RETN 
-25 Interleukin 8 IL8 28.21 Proto-oncogene c-Fos FOS 
-23.08 Chemokine (C-X-C Motif) Ligand 2 CXCL2 15.40 
Pim-3 Proto-Oncogene, 
Serine/Threonine Kinase PIM3 
-22.29 TNF receptor-associated factor 5 TRAF5 16.24 
Suppressor of cytokine signaling 
1  SOCS1 
-20.26 
Signal Transducer and Activator of 
Transcription 1 STAT1 11.66 Tumor necrosis factor TNFA 
-17.5 TNF receptor-associated factor 3 TRAF3 11.28 Toll-like receptor 4 TLR4 
-17.49 
Myeloid differentiation primary 
response MYD88 9.76 Epidermal growth factor EGF 
-13.3 TNF receptor-associated factor 6 TRAF6 9.13 Lymphotoxin-alpha LTA 
-12.9 Chemokine (C-C motif) ligand 20 CCL20 8.50 Nuclear receptor related 1 protein NR4A2 
-11.75 Interleukin 6 IL6 7.02 Ubiquitin C UBC 
-11.59 
Caspase 1, Apoptosis-Related 
Cysteine Peptidase CASP1 6.18 Adrenoceptor Beta 2, Surface ADRB2 
-9.95 B-Cell CLL/Lymphoma 3 BCL3 6.55 Interleukin-2 receptor alpha IL2RA 
-8.75 Prostaglandin E Receptor 2 PTGER2 4.42 
Sex Determining Region Y)-Box 
9 SOX9 
-8.73 
inhibitor of nuclear factor kappa-B 
kinase IKBKB 3.16 
Tumor Necrosis Factor Receptor 
Superfamily, Member 10b 
TNFRSF10
B 
-8.35 C-reactive protein CRP 3.99 Superoxide dismutase SOD1 
 -7.41 Plasminogen Activator PLAT 3.86 (Early Growth Response 2 EGR2 
-6.09 Toll-like receptor 2 TLR2 3.78 C-C chemokine receptor type 10  CCR10 
-5.87 Janus Kinase 2 JAK2 3.65 Vascular cell adhesion protein 1 VCAM1 
-5.57 
Mitogen-Activated Protein Kinase 
Kinase Kinase 1 
MAP3K
1 3.63 Endothelin 1 EDN1 
-5.55 Intercellular Adhesion Molecule 1 ICAM1 3.54 Jun Proto-Oncogene JUN 
-4.78 Complement Component 5 C5 3.38 
26S proteasome non-ATPase 
regulatory subunit 3 PSMD3 
-4.33 Leukotriene B4 Receptor 2 LTB4R2 3.31 Nuclear Receptor Subfamily 4 NR4A1 
-4.18 Nuclear factor NF-kappa-B p105 NFKB1 2.91 
Insulin-Like Growth Factor 
Binding Protein 2 IGFBP2 
-4.17 
Insulin-Like Growth Factor Binding 
Protein 1 IGFBP1 2.48 Retinoic acid receptor alpha RARA 
-4.09 Phospholipase C, Beta 4 PLCB4 2.46 Transforming growth factor beta TGFB1 
-3.99 Chemokine (C-C Motif) Ligand 2 CCL2    
-3.98 TNF receptor-associated factor 2 TRAF2    
-3.83 
Signal Transducer And Activator Of 
Transcription 3 STAT3    
-3.7 Colony Stimulating Factor 2 Receptor CSF2    
-3.54 
Tumor Necrosis Factor Receptor 
Superfamily, Member 1A 
TNFRSF
1A    
-3.32 
CAMP Responsive Element Binding 
Protein 1 CREB1    
-3.32 
Nuclear Factor Of Kappa Light 
Polypeptide Gene Enhancer In B-
Cells 2  NFKB2    
-3.16 
Insulin-Like Growth Factor Binding 
Protein 3 IGFBP3    
-2.95 Epidermal Growth Factor Receptor EGFR    
-2.84 
v-rel avian reticuloendotheliosis viral 
oncogene homolog REL    
-2.78 
Nuclear factor NF-kappa-B p105 
subunit NFKB1    
-2.77 
Transforming Growth Factor, Beta 
Receptor 1 TGFBR1    
-2.74 nterleukin 1 Receptor Antagonist IL1RN    
-2.43 tumor protein p53 TP53    
-2.35 
Mucosa-associated lymphoid tissue 
lymphoma translocation protein 1 MALT1    
-2.34 
V-Rel Avian Reticuloendotheliosis 
Viral Oncogene Homolog B RELB    
-2.09 Mitogen-Activated Protein Kinase 8 MAPK8    
Values are expressed as fold change in gene expression relative to vehicle treated control cells. Positive and negative values 
indicate up- and down-regulation of gene expression, respectively. A fold difference cut-off point was set at ≥2.5.  
  
 
Table 2: List of genes that were differentially dysregulated in cancerous ACHN cells compared to 
untreated RPTEC/TERT1 cells 
Genes with decreased expression Genes with increased expression 
Fold 
decrease Gene name Gene 
Fold 
increase Gene name Gene 
-53.30 Interleukin (IL)1-receptor 1  IL1R1 185.52 
Vascular cell adhesion 
molecule 1  VCAM1 
-51.65 
major histocompatibility complex, 
class I, A HLAA 23.24 
Chemokine (C-C Motif) 
Receptor 10 CCR10 
-46.38 interleukin (IL)1-receptor 1  IL1RN 20.88 
Connective Tissue Growth 
Factor CTGF 
-41.10 Superoxide dismutase 2 SOD2 18.96 
Insulin-Like Growth Factor 
Binding Protein 2 IGFBP2 
-39.13 Nuclear receptor related 1 protein NR4A2 5.86 Resistin RETN 
-29.53 TNF receptor-associated factor 3 TRAF3 3.99 Matrix Metallopeptidase 2 MMP2 
-27.81 
tumor necrosis factor a (TNF 
superfamily, member 2 TNFA 3.53 
Adrenoceptor Beta 2, 
Surface ADRB2 
-24.24 Interleukin 6 IL6 3.09 
Signal Transducer And 
Activator Of Transcription 1 STAT1 
-21.16 Interleukin 6 receptor IL6R 3.08 Phospholipase C, Beta 4 PLCB4 
-20.59 TNF receptor-associated factor 5 TRAF5 2.87 Early Growth Response-2 EGR2 
-18.65 C-reactive protein CRP 2.08 
Plasminogen activator 
inhibitor-1 PAI1 
-17.67 Chemokine (C-X-C Motif) Ligand 1 CXCL1 6.11 
(Interleukin 2 Receptor, 
Alpha IL2RA 
-16.81 Intercellular Adhesion Molecule 1 ICAM1 3.58 
TATA Box Binding Protein 
(TBP)-Associated Factor TRAF1 
-16.79 Janus Kinase 2 JAK2 2.55 Toll-Like Receptor 4 TLR4 
-15.28 
Insulin-Like Growth Factor Binding 
Protein 3 IGFBP3    
-14.84 
Colony Stimulating Factor 2 Receptor, 
Alpha CSF2    
-13.78 Transcription factor SOX-9 SOX9    
-13.60 Interleukin-23 IL23    
-12.45 
Mitogen-Activated Protein Kinase 
Kinase Kinase 1 MAP3K1    
-10.66 
Colony Stimulating Factor 2 Receptor, 
Alpha CSF1    
-9.45 Chemokine (C-X-C Motif) Ligand 2 CXCL2    
-8.77 
Transforming Growth Factor, Beta 
Receptor 1 TGFBR1    
-8.62 Vascular Endothelial Growth Factor A VEGFA    
-8.50 
Prostaglandin E Receptor 2 (Subtype 
EP2) PTGER2    
-8.10 Basal Cell Adhesion Molecule BCAM    
 -8.07 
Caspase 1, Apoptosis-Related Cysteine 
Peptidase CASP1    
-7.80 B-cell lymphoma 6 protein BCL6    
-7.22 liases for IKBKB Gene IKBKB    
-6.30 
Tumor Necrosis Factor Receptor 
Superfamily, Member 10 TNFRSF10A    
-6.07 
Inhibitor Of Kappa Light Polypeptide 
Gene Enhancer In B-Cells SCOS3    
Values are expressed as fold change in gene expression relative to vehicle treated control cells. Positive and negative values 
indicate up- and down-regulation of gene expression, respectively. A fold difference cut-off point was set at ≥2.5.  
 
 
 
Table 3: Summary of genes that were dysregulated in both carcinogen (KBrO3) treated RPTEC/TERT1 
and in cancerous ACHN cells compared to the untreated RPTEC/TERT1 cells 
Downregulated Upregulated 
BCL3 CTGF 
CASP1 PAI1 
CCL2 VCAM1 
CCL20 RETN 
CREB1 CCR10 
CRP IGFBP2 
CSF2 ADRB2 
CXCL1 EGR2 
CXCL2 PAI1 
ICAM1 IL2RA 
IGFBP1  
IGFBP3  
IKBKB  
IL1R1  
IL1RN  
IL6  
IL8  
JAK2  
LTB4R2  
MAP3K1  
MYD88  
NFKB1  
NFKB1  
NFKB2  
PTGER2  
REL  
RELB  
STAT3  
TGFBR1  
TLR2  
 TLR3  
TNFRSF1A  
TP53  
TRAF2  
TRAF3  
TRAF5  
TRAF6  
 
  
 3.4. Curcumin effectively reduced KBrO3 induced TRAF3 and IL1-R1 downregulation and CTGF 
upregulation 
To validate the results of the PCR array, individual TaqMan- based probe assays were used to measure the 
expression of TRAF3, IL1-R1, and CTGF quantitatively using qRT-PCR. The exposure of RPTEC/TERT1 to 
5.5mM KBrO3 significantly (p<0.001) inhibited TRAF3 and IL-1R1 gene expression compared to untreated or 
curcumin-treated cells (Fig.3a and 3b). In contrast, KBrO3 treatment significantly (p<0.01) upregulated CTGF 
gene expression in KBrO3-treated RPTEC/TERT1 compared with untreated or curcumin-treated cells (Fig.3c). 
More importantly, the co-treatment of 25µM curcumin with KBrO3 significantly (p<0.05) diminished the 
negative effect of KBrO3 on TRAF3 expression (Fig.3a), and induced a significant (p<0.01) reduction of the 
overexpressed CTGF level when combined with KBrO3 compared with KBrO3 alone (Fig.3c). However, the 
protective effect of curcumin on KBrO3 induced IL-1R1 suppression wasn’t significant (p>0.05), (Fig.3b). 
For further validation, we investigated the expression of CTGF at the protein level. In this case, we 
compared the CTGF repressor activity of curcumin with silymarin, a natural CTGF repressor[27] [28]. KBrO3 
clearly up-regulated CTGF protein expression, which was markedly repressed by curcumin. Strikingly, 
curcumin showed a higher CTGF repressor activity than silymarin when combined with KBrO3 compared with 
KBrO3-only treatment (Fig. 3d). 
 
  
Figure 3. Analysis of the effects of KBrO3 on TRAF3, IL-1R1, and CTGF gene expression, and the 
protective potential of curcumin.  
Fig.3 a,b) KBrO3 (5.5mM) treatment of  RPTEC/TERT1 for 24h onTRAF3 and IL-1 gene expression, 
respectively compared with the untreated or curcumin-treated cells. Tthe data represents three independent 
experiments. (*= P> 0.05) 
Fig.3 c,d) KBrO3 (5.5mM)- treatment of RPTEC/TERT1 for 24h on CTGF at both  mRNA and protein levels 
in comparison the untreated or curcumin-treated cells. The data represents three independent experiments 
(**=P < 0.01)  
3.5. Curcumin diminishes the deciliating effects of the genotoxic carcinogen KBrO3  
It has been reported that some renal carcinogens including KBrO3 induce ciliary loss [23]. For this reason, 
we investigated whether curcumin has a protective potential against KBrO3-induced deciliation. As shown in 
 Fig.4a (i) and (ii), RPTEC/TERT1 cells were treated with 0.1% DMSO (control) or with 25µM curcumin. 
Under both conditions, RPTEC/TERT1 exhibited well-defined tight junctional barriers between cells (green), 
and prominent cilia (red). Treating cells with 5.5mM KBrO3 (iii) resulted in disruption of the tight junctional 
protein ZO-1 and a complete loss of the ciliary marker protein, acetylated α-tubulin. The co-treatment of 
curcumin with KBrO3 (iv) minimized ciliary loss and junctional protein damage.  
To confirm the results, we investigated the effect of KBrO3 on Arl13b, a specific ciliary protein, using 
confocal microscopy. Very prominent and intact cilia were observed in both untreated and curcumin-treated 
cells, as shown in Fig.4b (i) and (ii), respectively. The exposure of RPTEC/TERT1 cells to 5.5mM KBrO3 for 
24h caused a significant loss of cilia. In contrast, the co-treatment of 25µM curcumin with KBrO3 clearly 
reduced the deciliating effect of KBrO3 on RPTEC/TERT1 cells (Fig.4b iv).  
We also examined gene expression levels of ZO-1 and Arl13b using TaqMan probe-based gene assays, 
Fig.4c and 4d. As seen in both figures, KBrO3 at 5.5 mM significantly down-regulated the expression of both 
ZO-1 (p<0.05) and Arl13b (p<0.01) compared with untreated or curcumin-treated cells. However, the co-
treatment of 25µM curcumin with KBrO3 significantly (p<0.01) reversed the negative effect of KBrO3 on ZO-
1 and Arl13b gene expression. 
 
 
 Figure 4. Effect of Curcumin on KBrO3 induced loss of primary cilia and disruption of tight junction 
proteins 
 
Fig.4a) KBrO3 (5.5mM) treatment of RPTEC/TERT1 for 24h on ciliary and junctional proteins in 
comparison with untreated or curcumin-treated cells. RPTEC/TERT1 cells were cultured in 8-well chamber 
slides and treated with after 10 days of 100% confluency. Confocal images (40x) show the primary cilia with 
red labelled , α-acetylated tubulin, while the green staining represents the tight junctional protein ZO-1.  
Hoechst 33342 was used to stain the nuclei (blue), scale 50µm. (i) 0.1% DMSO (control), (ii) curcumin 25 µM,  
(iii) 5.5 mM KBrO3 (ic10) , (iv) Co-treatment of curcumin + KBrO3. The images are representative of 3 
independent experiments.  Scale =50 µm. 
 
Fig.4b KBrO3 (5.5mM) treatment of RPTEC/TERT1 for 24h on a ciliary protein in comparison with 
untreated or curcumin-treated cells. Confocal images (40x) show the primary cilia with red labelled Arl13b.  
Hoechst 33342 was used to stain the nuclei (blue), scale 50µm. (i) 0.1% DMSO (control), (ii) curcumin 25 µM,  
(iii) 5.5 mM KBrO3 (ic10) , (iv) Co-treatment of curcumin + KBrO3. The images are representative of 3 
independent experiments   
 
Fig.4c,d) KBrO3 (5.5mM) treatment of  RPTEC/TERT1 for 24h on ZO-1 and Arl13b gene expression, 
respectively compared with the untreated or curcumin-treated cells.  The data represents three independent 
experiments.  *= p> 0.05, ** = p>0.01. 
 
  
4. Discussion 
Potassium bromate, KBrO3, a salt of the bromate ion, is a nephrotoxic and neurotoxic agent in humans 
and a proven carcinogen in animals [29, 30].  KBrO3 is considered a possible human carcinogen (IIb) according 
to the International Agency for Research on Cancer (IARC) [31]. It was used as a model of cancers in many in 
vivo studies [4, 32-34]   .  
The cytotoxic effects of KBrO3 were previously assessed by measuring the activity of the lactate 
dehydrogenase (LDH) enzyme. Akanji et al found that after administration of a single dose of KBrO3, LDH 
activity was significantly increased in rat renal and intestinal tissues compared to other tissues [35] . In addition, 
Ahmed et al reported that the release of LDH from KBrO3- treated cells was linked to KBrO3-induced oxidative 
stress [36]. In our model, we found that the co-treatment of KBrO3 with curcumin resulted in decreased LDH 
release which reflects the protective potential of curcumin against KBrO3-induced cytotoxicity. Curcumin has 
antioxidant, anti-inflammatory, and free radical scavenging activity. Its structure provides two methoxyphenyl 
groups and an enol form of β-diketone which  illicit typical radical trapping activity [37].  
 
         In this study, treating human renal RPTEC/TERT1 cells with IC10 or IC50 concentrations of KBrO3 
caused an increase of H2O2 and 8-OHdG levels suggesting that the induction of oxidative stress is one of the 
mechanisms by which KBrO3 induces its toxic and carcinogenic effects. We measured H2O2 levels as it is more 
stable than other oxidative species; also, H2O2 represents the precursor molecule of the hydroxyl radical that 
directly targets DNA and forms DNA adducts [38]. The co-treatment of KBrO3 with curcumin suppressed 
KBrO3 induced elevation of H2O2 and 8-OHdG levels at both toxic and subtoxic concentrations. Our findings 
are in line with a number of previous studies [39-42]. 8-OHdG is a biomarker for oxidative stress and 
carcinogenicity [43, 44]  and has been proven to be a factor in initiating and promoting the process of 
carcinogenesis [45].  It has been reported that reactive species such as reactive oxygen species (ROS) can attack 
nucleotide pools such as dGTP forming 8-OHdG. The adduct formed can bind adenine and cytosine nucleotide 
 bases causing A:G mismatch. If the mismatch is irreparable, G:C to A:T transversion, a mutation will form. 
This mutation is mainly detected in many proto-oncogenes and tumor suppressor genes. In addition, the 
formation of DNA adducts such as 8-OHdG can cause steric hindrance which affect the fidelity of DNA 
replication [46]. 8-OHdG is considered as an important biomarker to measure the extent of DNA damage 
following the exposure to cancer initiating agents. Furthermore, it is also considered as a cofactor of cancer 
initiation and promotion [47] 
.  
Curcumin's chemopreventive potential has been proven by many in vitro and in vivo studies. Much 
research has shown that curcumin can efficiently protect cells from H2O2 -induced oxidative cell injury [38, 48] 
. Due to its antioxidant potential, curcumin was shown to have the ability to reduce lipid peroxidation and DNA 
damage, while increasing the level of vitamin C, vitamin E, and total anti-oxidant capacity [49, 50]. 
Furthermore, curcumin has been shown to induce phase II metabolism while suppressing phase I metabolizing 
enzymes such as renal ornithine decarboxylase [51]. Because the catalase enzyme potentially detoxifies and 
decomposes H2O2 to H2O [52], the activation of catalase by curcumin is considered another effective way to 
counteract oxidative stress. In this study, KBrO3 was shown to suppress the anti-oxidant catalase enzyme which 
represents one mechanism by which KBrO3 increases oxidative stress in cells. Our finding is in agreement with 
a previous study [53]. Interestingly, curcumin effectively reversed KBrO3 induced catalase suppression, which 
suggests that this may be an important mechanism by which curcumin mediates its chemopreventive effects. 
Taken together, we can conclude that curcumin blocked the carcinogenic potential of KBrO3 by increasing 
catalase enzyme activity thus reducing H2O2 and 8-OHdG levels. 
Previous studies have shown that oxidative DNA damage causes activation of many inflammatory genes 
which creates a positive feedback loop leading to increased DNA damage, thus promoting cellular 
transformation and tumor progression [54-56]. Therefore to determine the role of inflammatory genes in our 
model, we measured a total of 192 target genes following the treatment of RPTEC/TERT1 cells with a subtoxic 
concentration of KBrO3 and compared the dysregulation status of the genes with the congruent genes in a human 
renal cancerous ACHN cell line. We found that CTGF was the most overexpressed gene following KBrO3 
treatment and the third most overexpressed gene in the cancerous ACHN cell line. To our knowledge, this is 
the first study to provide evidence of the increased expression of CTGF following KBrO3 treatment at both 
transcriptional and translational levels. There is abundant evidence from previous studies showing that CTGF 
can be overexpressed by oxidative stress conditions [57-60], and it has also been shown that CTGF is up-
regulated in many cancers [61-64]including  renal cell carcinomas [65]. Taken together, we propose that the 
carcinogenic potential of KBrO3 might be through DNA adduct formation and the dysregulation of several 
inflammatory-regulating genes including CTGF. We also compared the potential CTGF repressor activity of 
curcumin with silymarin, another chemopreventive agent with a well-known CTGF repressor activity [27, 66-
68]. Co-treatment of curcumin with KBrO3 significantly reduced the expression of CTGF at both RNA and 
protein levels. Our results are consistent with Zheng and Chen who found that curcumin reduced CTGF 
overexpression by interfering with upstream TGF-β signaling and TGF-β receptor activation. In addition to this, 
curcumin was found to induce GSH antioxidant synthesis and peroxisome proliferator-activated receptor 
(PPAR)-γ activation.  Furthermore, curcumin was shown to modulate extracellular matrix gene expression such 
as α1(I)-collagen fibronectin and α-smooth muscle actin (α-SMA) by interrupting TGF-β signaling including 
 its downstream effector, CTGF [69]. Curcumin halted the CTGF pathway via inhibition of ERK, P38 MAPK, 
and NF-KB pathways [70-72]. 
We have also shown that treating human renal RPTEC/TERT1 cells with KBrO3 negatively affected 
ciliary and junctional protein expression. KBrO3 caused a reduction in the number of ciliated cells and disturbed 
cellular borders. Our group has previously reported that KBrO3 induced RPTEC/TERT1 ciliary loss was 
accompanied by an increased proportion of cells at G2/S phase, and thus caused activation of cell cycle 
progression and proliferation [23]. We have found that curcumin protected RPTEC/TERT1 cells against KBrO3 
induced deciliation. Another study showed that curcumin exerted an anti-proliferative effect via inhibition of 
cell cycle regulators of hepatic cells when they were exposed to diethylnitrosamine, a genotoxic carcinogen 
[73]. Blackmore et al. found that curcumin targeted colorectal cancer cells by arresting the G2/M phase of the 
cell cycle through disruption of microtubular orientation and assembly, as well as chromosomal condensation 
and congression [74]. Taken together, these studies show that KBrO3 ’s deciliating effect caused loss of cellular 
differentiation and promoted cellular proliferation. Strikingly, such negative effects of KBrO3 were found to be 
significantly minimized by co-treatment with curcumin in our system. 
 We have also shown that treating cells with a subtoxic concentration of KBrO3 caused inhibition of IL-1 
and TRAF3 gene expression. However the impact of KBrO3 was reduced when treated in combination with 
curcumin.. Il-1 and TRAF3 were selected for further analysis due to their direct link with apoptosis-mediated 
cell death [75, 76] .  Furthermore, it has been found that IL-1 can regulate ciliary length. For instance, a study 
by Wann and Knight showed that ciliary length increased by approximately 50% following only 3 hours of 
exposure to IL-1. The mechanism of ciliary elongation is through a protein kinase A (PKA) dependent 
mechanism [77]. Therefore, by inhibiting IL-1 gene expression, KBrO3 can counteract apoptosis and induce 
cellular dedifferentiation. TRAF3 is a cytoplasmic component with E3 ubiquitin ligase activity; following the 
binding to CD40, TRAF3 activates B-lymphocyte cells. It has been found that mice homozygous for a null 
allele of TRAF3 develop B-cell lymphoma. It also participates in the inhibition of NF-KB signaling pathway, 
namely interacting with Act 1 in cancer cells.  Cells with mutant TRAF3 become cancerous due to the activation 
of NF-KB [78]. Generally, TRAF3 controls an alternative pathway of NF-KB activation with no effects on the 
classical pathway. TRAF3 negatively regulates NF-κB inducing kinase (NIK) levels, therefore the mutation of 
TRAF3 genes or activation of receptor-mediated proteasomal degradation is associated with the accumulation 
and auto-phosphorylation of NIK and activation of IKKα, which leads to the activation of NF-κB [79]. TRAF3 
is sequestered to the cell cytoskeleton via TRAF3 interacting protein 1 (TRAF3ip1) which is localized to the 
cilium and is necessary for ciliogenesis. TRAF3ip1 mutant cells have been shown to be incapable of generating 
a primary cilium [80].  
We have shown that KBrO3 induced downregulation of NF-KB gene expression at the mRNA level. 
However, no rescue effect was observed of curcumin against KBrO3-induced NF-KB downregulation 
(supplementary, Figure 1). 
A study by Wann et al suggested that primary cilia are considered an important influence on NF-KB 
activation, thus loss of cilia was associated with deregulation of NF-KB activation [81]. Furthermore, Sinha et 
al found that TRAF3 can participate in NF-KB activation through the x-linked ectodermal dysplasia receptor 
[82]. Therefore downregulation of TRAF3, NF-KB, and IL-1 gene expression and disruption of cilia by KBrO3 
might be important mechanisms by which to counteract apoptosis and induce cellular dedifferentiation in 
 carcinogenesis. However, further studies are required to investigate the effect of ciliary loss on the expression 
of inflammatory genes. 
A significant number of publications have described curcumin’s anti-inflammatory potential as an 
important property to curtail the progression of several diseases including cancers. Curcumin shows potent anti-
inflammatory potential  due to its direct regulatory effects on several transcription factors such as STAT, 
MAPK, and NF-KB, interleukins (ILs) such as TNF-a, IL-1,2,6,8 and 12. Furthermore, it has shown to inhibit 
lipoxygenase, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) enzymes activities [83-
85] 
Despite the broad spectrum of curcumin’s health benefits and the wide range of biological significance, 
its clinical applications are potentially limited due to poor bioavailability. The slight aqueous solubility, 
instability, and photo degradation of curcumin represent major obstacles that limit its use in different therapeutic 
applications. Therefore, more than 1500 papers had been published by  2015 to find suitable solutions for such 
fundamental dilemmas in the clinical use of curcumin [86]. Perhaps, the incorporation of curcumin in a 
phospholipid system to form a liposomal-curcumin complex is one of the successful trials to improve 
curcumin’s bioavailability. Conjugation of liposomal curcumin with different molecules such as polyethylene 
glycol and folic acid has been reported to highly extend the biological half-life and targetability of the liposomal 
curcumin. Therefore, a substantial improvement of both pharmacokinetics and pharmacodynamics of curcumin 
molecules was recorded following the administration of liposomal curcumin in vivo [87]. Other strategies 
include induction of structural modifications to improve curcumin;s in vivo stability and effectiveness. For 
instance, a recent study has shown that dimethoxy curcumin has a unique anti-tumor activity due to its ability 
to suppress the transcription factor activator protein-1 (AP-1) and induce degradation of androgen receptors 
(AR). At the same time, dimethoxy curcumin showed a high metabolic stability compared to curcumin itself 
[88]. While another study found that a modification in curcumin’s aromatic ring resulted in the formation of 10 
different curcumin analogues with more potent in vitro and in vivo anti-tumor activities than curcumin [89]In 
this study we provide significant evidence that the food additive KBrO3 induced carcinogenic alteration via 
induction of ROS and activation of several oncogenic genes, counteracting tumor suppressor genes and 
favouring cell dedifferentiation. To our knowledge, this is the first study to identify the dysregulated genes of 
KBrO3-treated normal kidney cells that might be implicated in KBrO3-induced carcinogenesis via compar them 
with the genes of renal cancerous cells. Furthermore, this is the first study to report another protective 
mechanism of curcumin via inhibition of KBrO3-induced cell dedifferentiation. 
In conclusion, the molecular mechanisms of curcumin chemoprevention have been investigated and are 
due in particular to its potential to block KBrO3 induced intracellular oxidative stress, DNA damage, and the 
dysregulation of signaling hubs that control inflammation, apoptosis, and cell differentiation which contribute 
to the pathogenesis and progression of KBrO3-induced renal cancer. Although challenges such as poor 
absorption and rapid elimination represent the major roadblocks in curcumin’s clinical applications, research is 
still ongoing to tackle these problems. However, the future seems bright particularly with the development of 
new curcumin analogues that are more potent, with higher bioavailability. Therefore, curcumin has considerable 
scope as a novel cancer prevention agent, due to its pleiotropic actions and in particular its cyto-protective and 
chemopreventive potential against chemical carcinogenesis. 
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